Hepatitis C: Controversies, strategies and challenges

European Journal of Surgery, Supplement

Volumn 164, Issue 582, 1998, Pages 65-70

  Gitnick, Gary ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; COMPLEMENTARY DNA; CONSENSUS INTERFERON; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; INTERFERON; KETOPROFEN; LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBOZYME; THYMOSIN ALPHA1; URSODEOXYCHOLIC ACID; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; ENZYME IMMUNOASSAY; GENOTYPE; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; PHLEBOTOMY; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; REVIEW;

HEPATITIS C; HUMANS; RISK FACTORS;

EID: 0032216789     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. 1. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus. JAMA 1990; 264: 2231-2235.
2. 2. Bhandari BN, Wright TL. Hepatitis C: an overview. Annual Review Medicine 1995; 46: 309-317.
3. 3. Bukh J. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Seminars in Liver Disease 1995; 5: 41-63.
4. 4. Causse X, Godinot H, Chevallier M, et al. Comparison of I or 3 MU of interferon aalfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
5. 5. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
6. 6. Chemello L, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-a in chronic hepatitis C. Annals of Internal Medicine 1996; 124: 1058-1060.
7. 7. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
8. 8. Di Bisceglie Am, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Eng J Med 1989; 321: 1506-1510.
9. 9. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.
10. 10. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-356.
11. 11. Kim JL, Morgenstem KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain completed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-355.
12. 12. Lai M-Y, Kao J-H, Yang P-M, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-1312.
13. 13. Love RA, Parge HE, Wichersham JA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87: 331-334.
14. 14. Love RA, Parge HE, Wickersham JA, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87: 331-342.
15. 15. Masiani R, Bellavita P, Fenili D, et al. Interferon alfa-2A therapy with cryoglulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-756.
16. 16. McFarlane IG. Hepatitis C and alcoholic liver disease (editorial). Am J Gastroenterol 1993; 88: 982-988.
17. 17. Nishigushi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
18. 18. Pol S, Berthelot P, Brechot C, and Franch Multicenter Study Group. Ribavirin-interferon vs interferon (26-IFN) alone in non-responders to -IFN in chronic hepatitis C. Hepatology 1996; 234: 356A.
19. 19. Poynard T, Bedoss P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Eng J Med 1995; 332: 1457-1462.
20. 20. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized as in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-789.
21. 21. Reichard O, et al. Interferon-alpha and ribavirin versus interferon-alpha alone as therapy for chronic hepatitis - A randomized double-blind placebo-controlled study. Hepatology 1996; 24: 356A.
22. 22. Reinhard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology 1994; 19: 280-285.
23. 23. Seeff LB. Natural history of viral hepatitis, type C. Seminars Gastrointestinal Dis 1995; 6: 20-27.
24. 24. Terrault N, Wright T. Hepatitis C virus in the setting of transplantation. Seminars in Liver Disease 1995; 15: 92-100.
25. 25. Wiber JC, Polito A. Serological and virological diagnosis tests for hepatitis C virus infection. Seminars in Gastroenterology Disease 1995; 6: 13-19.